Hepatitis C, ChronicHepCOPNCT00473993
Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland
An observational study of Hepatitis C, Chronic and Substance Abuse Treatment Centers, run by Seidenberg, Arztpraxis A., M.D..
Trial summary
Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine. While stabilized by an opioid maintenance treatment (OMT)chronic hepatitis C can be treated with pegylated interferon plus ribavirin. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Hepatitis C, Chronic, Substance Abuse Treatment Centers, Opioid-Related Disorders
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Jul 2007to Dec 2007
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: Patients in opioid maintenance treatment in the kanton of Zurich, Switzerland
Who may be able to join
- Medical practices and clinics involved in opioid maintenance treatment in the Kanton of Zurich, Switzerland
Who cannot join
None listed.
About this study
Official title: Hepatitis C Bei Opioidabhängigen in Der Praxis, Eine Querschnittsuntersuchung
Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine. While stabilized by an opioid maintenance treatment (OMT)chronic hepatitis C can be treated with pegylated interferon plus ribavirin. As not sufficiently known, the results are comparable to the results of the treatment of nonaddicts.
Our crossectional study investigates how many patients undergoing OMT are adequately investigated concerning hepatitis C. If not, why are they not adequately investigated and treated? Representative data are collected in the local clinics and medical practices involved in OMT in the Kanton of Zurich. The patients files are revised and the involved doctors are asked through a structured interview.
Read the detailed description
www.seidenberg.ch/hepcop.pdf
- Keywords
- Hepatitis C, Opioid Maintenance Treatment, Methadone, Buprenorphine, Heroin, Interferon, pegylated
- Medical subject headings
- Hepatitis C, Chronic, Opioid-Related Disorders, Hepatitis C
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2007 (estimated)
- Study startJul 2007
- Study completionDec 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatitis C, ChronicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Retrospective
Sponsor and investigators
- Lead sponsor
- Seidenberg, Arztpraxis A., M.D.
- Collaborators
- University of Zurich
- Investigators
- André Seidenberg, Dr.med., Study director, research fellow EHAM, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00473993
- Sponsor's protocol ID
- HepCOP Zurich
- Acronym
- HepCOP
- Status last verified
- May 2007
- First submitted
- 15 May 2007
- Last updated
- 16 Feb 2009
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 16 Feb 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hepatitis C Bei Opioidabhängigen in Der Praxis, Eine Querschnittsuntersuchung
- ClinicalTrials.gov ID
- NCT00473993
- Acronym / sponsor ID
- HepCOP / HepCOP Zurich
- Keywords
- Hepatitis C, Opioid Maintenance Treatment, Methadone, Buprenorphine, Heroin, Interferon, pegylated
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- Seidenberg, Arztpraxis A., M.D.
- Collaborators
- University of Zurich
- Study start
- Jul 2007
- Study completion
- Dec 2007 (actual)
- First posted
- 16 May 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hepatitis C viral infection is common among opioid addicts in Zurich, Switzerland. The majority undergoes a maintenance treatment with methadone, heroin or buprenorphine. While stabilized by an opioid maintenance treatment (OMT)chronic hepatitis C can be treated with pegylated interferon plus ribavirin. As not sufficiently known, the results are comparable to the results of the treatment of nonaddicts.
Our crossectional study investigates how many patients undergoing OMT are adequately investigated concerning hepatitis C. If not, why are they not adequately investigated and treated? Representative data are collected in the local clinics and medical practices involved in OMT in the Kanton of Zurich. The patients files are revised and the involved doctors are asked through a structured interview.
Detailed description
www.seidenberg.ch/hepcop.pdf
Study design
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Patients in opioid maintenance treatment in the kanton of Zurich, Switzerland
Key inclusion criteria (1 listed)
- Medical practices and clinics involved in opioid maintenance treatment in the Kanton of Zurich, Switzerland
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Feb 2009.
- download of the protocol of the HepCOP-studyLink provided by the sponsor.
Related trials for Hepatitis C, Chronic
RecruitingObservational study
Evaluation of Patients With Liver Disease
Hepatitis D, Hepatitis C
Active, not recruitingPhase 4
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Diabetes Mellitus, Hepatitis C, Chronic
RecruitingObservational study
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Chronic Liver Disease and Cirrhosis, Liver Cancer
Active, not recruitingPhase 4
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
Hepatitis C, Chronic, Pregnancy; Infection
Enrolling by invitationObservational study
Comparative Autoantibody and Immunologic Cell Marker Study
Autoimmune Diseases, Lupus Erythematosus, Systemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
André Seidenberg, Dr.med. study director
research fellow EHAM, University of Zurich
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatitis C, Chronic and Substance Abuse Treatment Centers, run by Seidenberg, Arztpraxis A., M.D..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Feb 2009. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Feb 2009.